TGFB1 and Thrombocytopenia: They demonstrated treatment with anti-GARP mAb (PIIO-1) showed effectiveness in murine cancer models by preventing thrombocytopenia, preferentially accumulating in the TME, and enhancing CD8+ T cell function while reducing TGF-β signaling.